Novavax: Sanofi Partnership Revives Business and Promises Billions in Revenue
Novavax is a biotechnology company that develops vaccines for diseases. The license agreement with Sanofi aims not only to co-commercialize a Covid-19 vaccine, but more importantly to develop a new combination product for high-risk seniors. The company will be eligible for clinical milestones and royalties that could add up to billions of dollars in revenue over the coming years and decades Novavax (NASDAQ: NVAX) is a biotechnology company developing vaccines. The company is in clinical development and is focused on delivering novel...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
Already registered? Log In
At an event, Tesla CEO Elon Musk explained his thoughts on the future of the electric car manufacturer and the influence of AI. Investors and Teslafans...
At Adobe MAX, the world's largest creative trade show, held from October 10 to October 12, the leading image-editing software provider unveiled new models...
array (
'ID' => '3918',
'post_author' =>
array (
'ID' => '3',
'user_url' => '',
'display_name' => 'Chiara Ferrario',
'user_registered' => '2023-09-12 13:13:33',
'nickname' => 'ChiaraFerrario',
'first_name' => 'Chiara',
'last_name' => 'Ferrario',
'description' => '',
'description_en' => '',
'description_es' => '',
'description_fr' => '',
'description_it' => '',
'freelancer' => '0',
'passive' => '0',
'twitter_link' => '',
'profile_image' => '',
'name' => 'Chiara Ferrario',
'name_short' => 'C. Ferrario',
'slug' => 'chiara-ferrario',
),
'post_date' => '2024-05-24 10:55:16',
'post_date_gmt' => '2024-05-24 08:55:16',
'post_content' => '
- Novavax is a biotechnology company that develops vaccines for diseases.
- The license agreement with Sanofi aims not only to co-commercialize a Covid-19 vaccine, but more importantly to develop a new combination product for high-risk seniors.
- The company will be eligible for clinical milestones and royalties that could add up to billions of dollars in revenue over the coming years and decades
Novavax (NASDAQ: NVAX) is a biotechnology company developing vaccines. The company is in clinical development and is focused on delivering novel products that prevent a broad range of diseases.
The Sanofi collaboration offers a potential revenue stream worth billions of dollars
The co-exclusive license agreement with Sanofi is a major step forward for Novavax and provides the company with a potential revenue stream worth billions of dollars. Under the agreement, Novavax and Sanofi will co-promote Novavax\'s adjuvanted COVID-19 vaccine globally, except for regions where Novavax has already partnered. In addition, the collaboration includes the development of novel COVID-19/Flu combination vaccines based on Novavax\'s Matrix-M adjuvant technology.
In return, Sanofi will pay a substantial sum to Novavax, including an upfront payment of $500 million and a minority interest of approximately $70 million. In addition, Novavax is entitled to $700 million in near-term milestones related to the development of COVID-19 and combination vaccines, as well as ongoing royalties from product sales. With the COVID-19 vaccine and the combination COVID/Flu vaccine alone, Novavax can collect a total of around $1.27 billion in the near future. The greatest opportunities arise from the potential development of new vaccines with Novavax\'s Matrix-M adjuvant.
The deal is an accolade
The Sanofi agreement underscores the potential of Novavax\'s technology platform and its ability to create value in the global vaccine market. Sanofi is one of the largest and best vaccine manufacturers in the world, so this potentially multi-billion dollar deal validates Novavax\'s technology both clinically and commercially. Sanofi would not enter into a deal of this magnitude if it was not confident in Novavax\'s nanoparticle technology and Matrix-M adjuvant. It is also important to note that this is not exclusively a COVID-19 vaccine deal. So there are several pieces that could provide Novavax with milestones and license fees in the coming years. It\'s not just a $1.3 billion deal for the near-term milestones, but a potential multi-billion dollar deal when you add in the Matrix M milestones and royalties over time. The hope is that Sanofi will leverage Matrix-M and use it to develop several new products to provide Novavax with a steady stream of partnership revenue over time.
The Sanofi deal will have an immediate, material and strategic impact on Novavax\'s future operations. Novavax indicated that half of the money will be received within 10 days of signing the Sanofi deal, which has already encouraged Novavax to update its 2024 financial guidance to the range of $970 million to $1.17 billion. In addition, the agreement allows Novavax to adopt a leaner operating model as Sanofi takes on some of the heavy lifting on the commercial side and provides reimbursement and supply arrangements. This allows Novavax to devote more resources and attention to its research and development efforts as well as its current pipeline programs that are in clinical development.
Bottom line: Now Novavax can essentially go full throttle by focusing its efforts on advancing its pipeline. They are already working on initiating Phase III clinical trials for their COVID-19 influenza combination vaccine (CIC) and their stand-alone influenza vaccine program in the second half of the year. If all goes well, these products could potentially be on the market by 2026.
',
'post_title' => 'Novavax: Sanofi Partnership Revives Business and Promises Billions in Revenue',
'post_excerpt' => '',
'post_status' => 'publish',
'comment_status' => 'open',
'ping_status' => 'open',
'post_password' => '',
'post_name' => 'novavax-sanofi-partnership-revives-business-and-promises-billions-in-revenue',
'to_ping' => '',
'pinged' => '',
'post_modified' => '2024-05-24 10:55:16',
'post_modified_gmt' => '2024-05-24 08:55:16',
'post_content_filtered' => '',
'post_parent' => '0',
'guid' => 'https://tradertimes.com/wordpress/?p=3918',
'menu_order' => '0',
'post_type' => 'post',
'post_mime_type' => '',
'comment_count' => '0',
'_encloseme' => '1',
'_pingme' => '1',
'magazine' =>
array (
'ID' => '3922',
'post_title' => 'The Trader Times #96 dated May 24, 2024',
'post_content' => '',
'post_date' => '2024-05-24 10:51:11',
'post_type' => 'tradertimes',
'post_mime_type' => '',
'post_parent' => '0',
),
'seo_description' => '',
'seo_image' => '',
'seo_title' => '',
'teaser' => '',
'category' =>
array (
9 =>
array (
'term_id' => '9',
'term_taxonomy_id' => '9',
'name' => 'Top Stories',
'slug' => 'top-stories',
'description' => '',
'parent' => '0',
'lang_term_taxonomy_id' => '8',
'lang_term_id' => '8',
'lang_name' => 'English',
'lang_slug' => 'en',
'translations' =>
array (
'de' => 1,
'en' => 9,
'es' => 13,
'fr' => 17,
'it' => 21,
),
'seo_title' => '',
'seo_description' => '',
'seo_image' => '',
'sub_ids' =>
array (
0 => 9,
),
'link' => '/top-stories/',
),
),
'link' => '/top-stories/novavax-sanofi-partnership-revives-business-and-promises-billions-in-revenue-3918.html',
'image' =>
array (
'ID' => '3917',
'post_title' => 'Influenza vaccine concept with syringe and bottles of vial with copy space - 3D illustration',
'post_content' => '',
'post_date' => '2024-05-24 09:39:45',
'post_type' => 'attachment',
'post_mime_type' => 'image/jpeg',
'post_parent' => '3916',
'src' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-scaled.jpeg',
'width' => 2560,
'height' => 1445,
'sizes' =>
array (
'thumbnail' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-150x150.jpeg',
'width' => 150,
'height' => 150,
'mime-type' => 'image/jpeg',
'filesize' => 14148,
),
'1536x1536' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-1536x867.jpeg',
'width' => 1536,
'height' => 867,
'mime-type' => 'image/jpeg',
'filesize' => 104806,
),
'2048x2048' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-2048x1156.jpeg',
'width' => 2048,
'height' => 1156,
'mime-type' => 'image/jpeg',
'filesize' => 155386,
),
'teaser' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-632x280.jpeg',
'width' => 632,
'height' => 280,
'mime-type' => 'image/jpeg',
'filesize' => 31926,
),
'content' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-1296x3500.jpeg',
'width' => 1296,
'height' => 3500,
'mime-type' => 'image/jpeg',
'filesize' => 279048,
),
'fb' =>
array (
'file' => 'https://tradertimes.com/files/2024/05/AdobeStock_384551058-1200x628.jpeg',
'width' => 1200,
'height' => 628,
'mime-type' => 'image/jpeg',
'filesize' => 73500,
'cpt_last_cropping_data' =>
array (
'x' => 0,
'y' => 0,
'x2' => 2560,
'y2' => 1339,
'original_width' => 2560,
'original_height' => 1445,
),
),
),
),
'translations' =>
array (
'de' =>
array (
'post_title' => 'Novavax: Sanofi-Partnerschaft belebt das Geschäft wieder und verspricht Einnahmen in Milliardenhöhe',
'post_name' => '',
'ID' => '3916',
'post_type' => 'post',
'link' => '/de/top-storys/-3916.html',
),
'en' =>
array (
'post_title' => 'Novavax: Sanofi Partnership Revives Business and Promises Billions in Revenue',
'post_name' => 'novavax-sanofi-partnership-revives-business-and-promises-billions-in-revenue',
'ID' => '3918',
'post_type' => 'post',
'link' => '/top-stories/novavax-sanofi-partnership-revives-business-and-promises-billions-in-revenue-3918.html',
),
'es' =>
array (
'post_title' => 'Novavax: la asociación con Sanofi revitaliza el negocio y promete ingresos multimillonarios',
'post_name' => 'novavax-la-asociacin-con-sanofi-revitaliza-el-negocio-y-promete-ingresos-multimillonarios',
'ID' => '3919',
'post_type' => 'post',
'link' => '/es/noticias-principales/novavax-la-asociacin-con-sanofi-revitaliza-el-negocio-y-promete-ingresos-multimillonarios-3919.html',
),
),
)
